Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
Home > UCLA Neuro-Oncology: Research Publications   
UCLA Neuro-Oncology: Research Publications
A listing of research findings by UCLA Neuro-Oncology and in cooperation with their research partners.
Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.
AJNR Am J Neuroradiol


Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
AJNR Am J Neuroradiol


Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
Cancer Chemother Pharmacol


Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
J Neurooncol


Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival.
AJNR Am J Neuroradiol


Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas.
J Magn Reson Imaging


Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Neuropathol Appl Neurobiol


Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
J Neurooncol


Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.
Neuro Oncol


Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.
J Nucl Med.


An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Cancer Discov


Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
Neuroimage


Will kinase inhibitors make it as glioblastoma drugs?
Curr Top Microbiol Immunol


Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
Cancer Chemother Pharmacol


3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
J Nucl Med


Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells.
Mol Cancer Res


Oncogenic EGFR signaling activates an mTORC2-NF-?B pathway that promotes chemotherapy resistance.
12/1/2011


Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
J Clin Oncol


The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma.
Semin Oncol


Discriminant analysis of F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
Clin Cancer Res


It is time to include patients with brain tumors in phase I trials in oncology.
J Clin Oncol.


Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
Neuro Oncol.


Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma.
Neuro Oncol.


Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
J Neurooncol.


Phase II study of aflibercept in recurrent malignant glioma: a north american brain tumor consortium study.
J Clin Oncol.


Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.
J Neurooncol.


Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.
Magn Reson Med.


Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept.
Clin Cancer Res.


International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Neuro Oncol.


Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.
AJNR Am J Neuroradiol.


AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Adv Ther.


Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.
Neuro Oncol.


Clinical trial end points for high-grade glioma: the evolving landscape.
NeuroOnc
p21310734

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.
NeuroOncology
PMID:21297127

Discriminant analysis of F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
Clin Cancer Res
17(20):6553-62. doi: 10.1158/1078-0432.CCR-10-3290. Epub 2011

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
J Clin Oncol. 2011 Jan 10;29(2):142-8.


New strategies in the molecular targeting of glioblastoma: how do you hit a moving target?
Clin Cancer Res.
PMID:21208902

Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
J Nucl Med
51(10):1532-8 PMID: 20847166

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
Neuro Oncol.
1061-70.

A Phase I Trial of Tipifarnib with Radiation Therapy, with and without temozolomide, for Patients with Newly Diagnosed Glioblastoma.
Int J Radiat Oncol Biol Phys
PMID: 20934264

Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation.
Pediatr Blood Cancer
(4):644-51;PMID: 20589659

Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases.
J Neurooncol
PMID: 20872044

Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach.
Phys Med Biol.
55(12):3271-85.

mTOR signaling in glioblastoma: lessons learned from bench to bedside.
Neuro-Onc


Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
J Nucl Med.
51(5):720-7.

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
J Clin Oncol
28(11):1963-72.

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.
Proc Natl Acad Sci U S A.
107(14):6459-64

AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas.
Cell Cycle


A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Neuro Oncol.
12(1):87-94.

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Neuro-Onc


Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
Nat Genet.
42(1):77-82.

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Science Signaling
2(101):ra82.

Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model.
Cancer Res
PMID: 19934335 ; 69(23):9133-40

Genomic Landscape of Meningiomas.
Brain Pathol.
PMID: 20015288

Bevacizumab for recurrent ependymoma.
Neurology
73(20):1677-80.PMID: 19917990

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
J Clin Oncol.
(28):4733-40; PMID: 19720927

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Cancer Res
PMID: 19690143 ; 69(17):6889-98

Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone.
J Neurooncology
PMID: 19655089

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
Proc Natl Acad Sci U S A
PMID: 19625624

Striking the balance between PTEN and PDK1: it all depends on the cell context.
Genes Dev
PMID: 19651981

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.
Cancer Cell
PMID: 19573811 ; 16(1):44-54.

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.
Neurotherapeutics
PMID:19561256 ; 252(1):182-9.

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
Radiology
252(1):182-9.PMID: 19561256

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
J Neurooncology
PMID: 19562255

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Proc Natl Acad Sci U S A.
106(23):9435-40 PMID: 19478061

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
J Neurooncology
PMID: 19468690

Neurosphere formation is an independent predictor of clinical outcome in malignant glioma.
Stem Cells
(4):980-7. PMID: 19353526

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
Neurology
7;72(14):1217-22.

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
J Neurooncol.
183-9

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
J Neurooncol.
91(2):175-82

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
J Clin Oncol
26(34):5610-7

A tool for improving the longitudinal imaging characterization for neuro-oncology cases.
AMIA Annu Symp Proc.
712-6.

Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age.
BMC Med Genomics


Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.
N Engl J Med
359(5):539-41

(18)F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience.
Eur J Radiol.
PMID: 18511228

Safety of anticoagulation use and bevacizumab in patients with glioma.
Neuro Oncol
PMID: 18436627

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
Neuro Oncology
PMID: 18356283

Time course of imaging changes of GBM during extended bevacizumab treatment
J Neurooncol.
PMID: 18389177

Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability.
Int J Radiat Oncol Biol Phys
PMID: 18355978

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
PLoS Med.
PMID: 18215105

Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age.
BMC Med Genomics


Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age.
BMC Med Genomics


Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
Clin Cancer Res
PMID: 18223223

Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
Clin Cancer Res
PMID: 18223223

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
Clin Cancer Res
PMID: 18094423

Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Proc Natl Acad Sci
PMID: 18077431

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
Clin Cancer Res
PMID: 18056194

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study
J Clin Oncol
PMID: 17947718

18F-FDOPA kinetics in brain tumors.
J Nucl Med
1651-61. PMID: 17873130

Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells.
J Neurosci Res


Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Cancer Chemother Pharmacol


Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2
Clin Cancer Res
PMID: 17473188 (9):2592-8.

(18)F-fluorothymidine kinetics of malignant brain tumors.
Eur J Nucl Med Mol Imaging.
PMID: 17295039

High-throughput oncogene mutation profiling in human cancer.
Nat Genet
PMID: 17293865

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.
Clin Cancer Res
PMID: 17255257

Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain.
PLoS Medicine
PMID: 17177598 ; 3(12):e485

Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target.
Proc Natl Acad Sci
103(46):17402-7; PMID: 17090670

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
J Neurooncol
PMID: 17031561

Primary glioblastomas express mesenchymal stem-like properties.
Mol Cancer Res.
PMID: 16966431 ;4(9):607-19.

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Clin Cancer Res
12(16):4899-907. PMID: 16914578

Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells.
Cancer Res.
66(16): 7864-9 PMID: 16912159

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

 


J Clin Oncol.
24(22):3651-6. PMID: 16877733

18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
J Nucl Med.
47(6):904-11. PMID: 16741298

Using molecular information to guide brain tumor therapy.
Nat Clin Pract Neurol
232-3. PMID: 16932555

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Neurology
66(8):1258-60. PMID: 16636248

Distinct transcription profiles of primary and secondary glioblastoma subgroups.
Cancer Research
66(1):159-67. PMID: 16397228

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
N Engl J Med.
353(19):2012-24. N Engl J Med. 2006 Feb 23;354(8):884. PMID: 16282176

MR imaging correlates of survival in patients with high-grade gliomas.
AJNR Am J Neuroradiol
26(10):2466-74. PMID: 16286386

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
J Clin Oncol.
23(27):6647-56. PMID: 16170172

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
Clin Cancer Res.
1;11(15):5515-25. PMID: 16061868

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
Invest New Drugs.
23(4):357-61. PMID: 16012795

Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
J Biol Chem.
22;280(29):26953-64. Epub 2005 May 20. PMID: 15908427

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
J Nucl Med.
46(6):945-52. PMID: 15937304

Robustness of gene expression profiling in glioma specimen samplings and derived cell lines.
Brain Res Mol
20;136(1-2):99-103. PMID: 15893592

EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Cancer Biol Ther.
3(12):1243-9. Epub 2004 Dec 14. PMID: 15611621

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
J Clin Oncol.
1;22(21):4282-9. PMID: 15514370

Brain tumor treatment: chemotherapy and other new developments.
Semin Oncol Nurs.
20(4):260-72. Review. PMID: 15612602

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
Invest New Drugs.
22(4):427-35. PMID: 15292713

DNA-microarray analysis of brain cancer: molecular classification for therapy.
Nat Rev Neurosci.
5(10):782-92. Review. PMID: 15378038

Gene expression profiling of gliomas strongly predicts survival.
Cancer Res.
15;64(18):6503-10. PMID: 15374961

Prediction of neurocognitive outcome in adult brain tumor patients.
J Neurooncol.
67(1-2):245-53. PMID: 15072475

p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Oncogene.
12;23(6):1283-90. PMID: 14961077

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Neuro-oncolgy
6(1):44-54. PMID: 14769140

Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line.
Lab Invest
84(1):8-20. PMID: 14631378

Oncodiagnosis panel: 2002. Patient's symptoms not related to the lesion seen in the MR images.
Radiographics.
23(6):1591-611. PMID: 14635615

Oncodiagnosis panel: 2002. Metastatic NSCLC.
Radiographics.
23(6):1591-611 PMID: 14628846

Oncodiagnosis panel: 2002. Patient's symptoms not related to the lesion seen in the MR images.
Radiographics.
23(6):1591-611. PMID: 14635615

Gene expression profiling identifies molecular subtypes of gliomas.
Oncogene.
31;22(31):4918-23. PMID: 12894235

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
J Clin Oncol.
15;21(12):2305-11. PMID: 12805331

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Cancer Res.
1;63(11):2742-6. PMID: 12782577

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cancer
1;97(9 Suppl):2381-6. PMID: 12712460

Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy.
Cancer Biol Ther.
2(3):242-7. Review. PMID: 12878856

Identification of molecular subtypes of glioblastoma by gene expression profiling.
Oncogene.
17;22(15):2361-73. PMID: 12700671

Targeted molecular therapy of GBM.
Brain Pathol.
13(1):52-61. Review. PMID: 12580545

Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging.
Magn Reson Med.
48(3):411-8. PMID: 12210904

Predicting major depression in brain tumor patients.
Psychooncology.
11(3):230-8. PMID: 12112483

Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Am J Clin Oncol
204-8. PMID: 11943904

A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study
Neuro-oncology
4(2):109-14. PMID: 11916502

Mapping therapeutic response in a patient with malignant glioma.
J Comput Assist Tomogr
25(4):529-36. PMID: 11473181

Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery.
Radiology.
218(3):724-32. PMID: 11230646

Tracking tumor growth rates in patients with malignant gliomas: a test of two algorithms.
AJNR Am J Neuroradio
22(1):73-82. PMID: 11158891

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Neuro-Oncology
3(1):46-54. PMID: 11305417

Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma.
J Neurooncol
50(3):215-26. PMID: 11263501

Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy.
AJNR Am J Neuroradiol
21(3):471-8. PMID: 10730637

Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas.
Neurosurgery
44(2):270-8; discussion 278-9. PMID: 9932880

Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma.
Magn Reson Med
41(1):2-7. PMID: 10025604

Topographical and temporal specificity of human intraoperative optical intrinsic signals.
Neuroreport.
3;9(11):2557-63. PMID: 9721932

Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow.
J Neurooncol
35(2):121-31. PMID: 9266448

Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen.
J Neurooncol
35(1):39-45. PMID: 9266439

Pharmacological blood-brain barrier modification for selective drug delivery.
J Neurooncol
26(2):125-32. Review. PMID: 8787854

Novel brainstem syndrome associated with prostate carcinoma.
Neurology
43(12):2591-6. PMID: 8255462

Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room.
Brain Topogr.
5(1):53-8. PMID: 1463660


* Published: Friday, October 20, 2017 : 2:44:58 PM PT

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2017 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2017 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:10/20/2017 2:44:58 PM PST]